Stephen Brady is slated to become the Chairman of the board of directors of Tempest Therapeutics upon the closing of a strategic acquisition.
Stephen Brady is slated to become the Chairman of the board of directors of Tempest Therapeutics upon the closing of a strategic acquisition. This acquisition by Tempest Therapeutics involves new dual-CAR T programs from Factor Bioscience Inc. and is expected to close in early 2026.
Full founder directory · Investor directory · Company funding database · Fundraising library